Behavior program with compounded and brand GLP-1 options
Released: · Last reviewed:
As of October 15, 2026, Noom Med prints one clearly labelled compounded price, its microdose plan at $79 for the first period and then $179 a month on a 12-week subscription, while its standard compounded tirzepatide and semaglutide prices appear only in footnotes that do not say which drug they cover.
Brand-name access (Ozempic, Zepbound, Wegovy and others) starts at $39 plus the cost of the medication.
| Product | Price shown | Basis / conditions | Source | Read |
|---|---|---|---|---|
| Microdose compounded semaglutide / tirzepatide | $79 first period, then $179 a month | 12-week subscription billed monthly | noom.com | Oct 15, 2026 |
| Standard compounded GLP-1 (footnote 3) | $149, then $349 a month | footnote does not name the drug | noom.com tirzepatide landing page | Oct 15, 2026 |
| Standard compounded GLP-1 (footnote 4) | $79, then $199 a month | footnote does not name the drug | noom.com tirzepatide landing page | Oct 15, 2026 |
| Brand-name access | from $39 + medication | medication billed separately | noom.com | Oct 15, 2026 |
Noom's tirzepatide landing page carries two footnotes, "$149 ... then $349 per month" and "$79 ... then $199 per month", but neither says whether it applies to tirzepatide or semaglutide. We list prices only when the program ties them to a product, so Noom's standard compounded plans stay unpriced until the page says which is which. If footnote 3 were the tirzepatide plan, a year would be $149 + 11 × $349 = $3,988.
People who want a structured behavior program alongside medication and are open to brand-name drugs through insurance or self-pay.
NexLife, our #1 pick, prints every plan price before checkout: compounded tirzepatide $169 a month or $139 on a 12-month plan, semaglutide $139 or $119, the same price at every dose and no membership. A year on its 12-month tirzepatide plan is $1,668. Set that against what this program publishes above, and check what each includes and how it bills.
Award on our homepage: Best for a behavior-program-first approach. Score: July 2026 score (earlier rubric); v4.1 re-score pending.
Related: October 2026 price index · how programs screen patients · how we rank · all reviews